Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry programHung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registryTyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.Infectious Diseases and Therapy|April 28, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in TaiwanChun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, et al.The Kaohsiung Journal of Medical Sciences|June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in TaiwanSzu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.Hepatology International|March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registryTe-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.The Kaohsiung Journal of Medical Sciences|January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in TaiwanSzu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.Scientific Reports|December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in TaiwanChung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.Pageof 6